Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They ...

Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...

H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

H.C. Wainwright initiated coverage of Veritone (VERI) with a Buy rating and $6 price target Veritone designs, develops, and distributes ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's ...